Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

5.640 +0.240 (+4.44%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
These names are benefitting from M&A, clinical data and promising regulatory actions. 
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Why IPO Stock Amylyx Pharmaceuticals Is Beginning To Heat Up — Again
Could this FDA action turn things around for Amylyx in September? 
Via Investor's Business Daily
Here's How Citi Views Amylyx Pharma
Via Benzinga
What 4 Analyst Ratings Have To Say About Amylyx Pharma
Within the last quarter, Amylyx Pharma (NASDAQ:AMLX) has observed the following analyst ratings: 
Via Benzinga
Why Stealth BioTherapeutics Shares Are Surging Today?
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by... 
Via FinancialNewsMedia
Exposures COVID-19
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Why Is Novavax (NVAX) Stock Rallying Today?
Novavax (NVAX) stock is taking off on Tuesday after the vaccine company got approval for the expanded use of its Covid-19 vaccine in Europe. 
Via InvestorPlace
Amylyx (AMLX) Stock Spikes 13% as FDA Resumes Discussion of ALS Drug
A new wrinkle in the story of Amylyx Pharmaceuticals' ongoing battle against ALS bodes well for patients, and for AMLX stock holders. 
Via InvestorPlace
Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session
Gainers Ra Medical Systems, Inc. (NASDAQ: RMED) shares jumped 69.6% to $0.5240 after the company announced it has received FDA 510(k) clearance for its DABRA 2.0 catheter. 
Via Benzinga
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before. 
Via Investor's Business Daily
Canada Approves Amylyx's ALS Drug; FDA To Consider Approval In September
The Canadian government has given its approval to AMX0035, a new drug from Cambridge, Massachusetts-based Amylyx Pharmaceuticals Inc. 
Via Benzinga
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It... 
Via FinancialNewsMedia
Mid-Afternoon Market Update: Gold Drops 1%; Sprague Resources Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
Amylyx Pharmaceuticals Shares Shoot Up As FDA Extends Review Of NDA For Neurodegenerative Disease Candidate
The U.S. Food and Drug Administration (FDA) has extended the review of New Drug Application (NDA) by three months, submitted by Amylyx Pharmaceuticals (NASDAQ: AMLX) for its lead drug candidate AMX0035... 
Via Benzinga
82 Biggest Movers From Yesterday
Gainers Comera Life Sciences Holdings, Inc. (NASDAQ: CMRA) gained 126.5% to settle at $2.65 on Tuesday. 
Via Benzinga
Novavax (NVAX) Stock Falls 25% on FDA Heart Inflammation Warning
Novavax (NVAX) stock is falling on Friday after the FDA requested a heart inflammation warning for the company's Covid-19 vaccine. 
Via InvestorPlace
83 Biggest Movers From Yesterday
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly... 
Via Benzinga
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
Mid-Day Market Update: Nasdaq Down 300 Points; Turning Point Therapeutics Shares Jump
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping more than 300 points on Friday. 
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. 
Via Benzinga
Why Is Amylyx Pharmaceuticals (AMLX) Stock Up 23% Today?
Amylyx Pharmaceuticals (AMLX) stock is rising higher on Friday following an update from the U.S. Food and Drug Administration (FDA). 
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; US Economy Adds 390,000 Jobs In May
U.S. stocks traded lower this morning, with the Dow Jones dropping around 150 points on Friday. 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.